CTMX Stock Forecast: CytomX Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.03
−0.98% on the day

The median 12-month analyst price target for CytomX Therapeutics, Inc. is $12. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 46 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$446.9M
Ticker Nerd rank
46/ 100
Median analyst target
$12
Analysts covering
8
Revenue$1.4M−92.4% y/y
Operating income−$23.8M
Net income−$20.7M
Free cash flow−$18.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.5%
1M
−19.1%
YTD
−52.3%
1Y
−46.2%
From 52W high
−69.9%
From 52W low
+8.0%
$1.88
$6.75
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores CytomX Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
46/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
74
Quality
70
Value
67
Revisions
49
Momentum
42
Volatility
42
Issuance
35
Growth
15

Accruals (74): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (15): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CTMX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CTMX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26CTMXHigh $16Median $12Low $5

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8
Buy
0
Hold
0
Sell
$5
Low
$12
Median
$16
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
12 Nov 2026JP MorganMaintainsOverweight$11 → $12
6 Nov 2026WedbushMaintainsOutperform$11 → $12
13 Aug 2026JP MorganMaintainsOverweight$12 → $11
10 Aug 2026GuggenheimMaintainsBuy$15 → $14
11 May 2026HC Wainwright & Co.MaintainsBuy$17 → $11
23 Mar 2026Piper SandlerMaintainsOverweight—
19 Mar 2026BarclaysMaintainsOverweight—
18 Mar 2026GuggenheimMaintainsBuy—
18 Mar 2026JefferiesMaintainsBuy—
17 Mar 2026WedbushMaintainsOutperform—
16 Mar 2026HC Wainwright & Co.MaintainsBuy—
16 Mar 2026JP MorganUpgradeOverweight—
9 Mar 2026GuggenheimReiteratesBuy—
4 Feb 2026BarclaysMaintainsOverweight—
4 Feb 2026Cantor FitzgeraldMaintainsOverweight—
20 Jan 2026BarclaysMaintainsOverweight—
20 Jan 2026GuggenheimInitiatesBuy—
20 Jan 2026Piper SandlerMaintainsOverweight—
11 Nov 2025HC Wainwright & Co.MaintainsBuy—
21 Oct 2025BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CTMX.

Market Radar

This page is one stock. Monday covers all of them.

CTMX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CTMX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, CytomX Therapeutics, Inc. returned −46.2% against +6.9% for the S&P 500, dividends included.

CTMX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Jan 26Apr 26Jul 26Oct 26CTMXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CTMX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
33.3×

Cheaper than 6% of US stocks

Price / book
1.6×

Cheaper than 51% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−43.6%

Higher than 23% of US stocks

Return on assets
−22.7%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CytomX Therapeutics, Inc. has a market value of $446.9M and an enterprise value of $103.3M.

  • Revenue in the twelve months to 30 June 2026: $18.3M. The latest quarter shrank 92.4% year on year.

  • Net income over the same four quarters: −$79.7M, a −435.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$82.5M.

  • Shares outstanding: 217.9M.

  • CytomX Therapeutics, Inc. employs 69 people — $265K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

CTMX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CTMXCytomX Therapeutics, Inc.$446.9M46
ASMBAssembly Biosciences, Inc.$439.7M79
CAPRCapricor Therapeutics, Inc.$436.5M13
OCSOculis Holding AG$435.8M30
PRTAProthena Corp. Plc$442.5M90
BLSMBlossomhill Therapeutics, Inc.$444.6M1
INDPIndaptus Therapeutics, Inc.$433.1M25

Take a look at CTMX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own CytomX Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CTMX

What is the CTMX stock price forecast for 2026-2027?

The median 12-month analyst price target for CytomX Therapeutics, Inc. is $12, with estimates ranging from $5 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CTMX stock a buy right now?

Of the 8 analysts covering CytomX Therapeutics, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CytomX Therapeutics, Inc. 46 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CTMX?

As at 21 Nov 2026, CytomX Therapeutics, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (74 of 100).

Will CTMX stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts is $12, and Ticker Nerd's factor model ranks CytomX Therapeutics, Inc. 46 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CTMX stock forecast for 2030?

No analyst covering CytomX Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTMX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $16 over the next 12 months.

How has CTMX stock performed over the past year?

CytomX Therapeutics, Inc. returned -46.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CytomX Therapeutics, Inc. do?

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. The company develops conditionally activated biologics through its Probody therapeutic platform, with the goal of localizing activity to the tumor microenvironment and limiting effects on healthy tissue.

Company

About CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. The company develops conditionally activated biologics through its Probody therapeutic platform, with the goal of localizing activity to the tumor microenvironment and limiting effects on healthy tissue. Its current pipeline spans multiple cancer-focused modalities, including antibody-drug conjugates, T-cell engagers, and immune-modulating therapies such as cytokines. CytomX Therapeutics also advances programs aimed at difficult-to-treat tumors, supporting research and development across a range of solid-tumor indications. Headquartered in South San Francisco, California, CytomX Therapeutics plays a specialized role in the biotechnology market as a developer of targeted cancer therapeutics designed for precision and selectivity.

CEO Dr. Sean A. McCarthy DPHIL · 69 employees · United States · https://www.cytomx.com